Geneva Capital Management LLC Sells 9,931 Shares of Novanta Inc. $NOVT

Geneva Capital Management LLC lowered its stake in shares of Novanta Inc. (NASDAQ:NOVT) by 1.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 979,038 shares of the technology company’s stock after selling 9,931 shares during the period. Novanta accounts for 1.7% of Geneva Capital Management LLC’s holdings, making the stock its 17th biggest position. Geneva Capital Management LLC owned about 2.74% of Novanta worth $98,051,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently made changes to their positions in the stock. Pilgrim Partners Asia Pte Ltd acquired a new position in Novanta during the third quarter worth $36,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Novanta in the 3rd quarter valued at about $40,000. Harbor Investment Advisory LLC increased its stake in shares of Novanta by 47.1% during the 3rd quarter. Harbor Investment Advisory LLC now owns 987 shares of the technology company’s stock worth $99,000 after purchasing an additional 316 shares during the last quarter. Van ECK Associates Corp raised its holdings in shares of Novanta by 17.2% in the 3rd quarter. Van ECK Associates Corp now owns 1,627 shares of the technology company’s stock valued at $163,000 after purchasing an additional 239 shares during the period. Finally, Inceptionr LLC bought a new stake in shares of Novanta in the 2nd quarter valued at about $213,000. Institutional investors and hedge funds own 98.35% of the company’s stock.

Novanta Stock Down 3.2%

Shares of NOVT opened at $123.14 on Wednesday. The firm has a market cap of $4.39 billion, a P/E ratio of 84.34 and a beta of 1.61. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.80 and a current ratio of 3.69. Novanta Inc. has a 52 week low of $98.27 and a 52 week high of $149.95. The firm’s 50-day simple moving average is $135.02 and its 200 day simple moving average is $121.13.

Novanta (NASDAQ:NOVT) last issued its quarterly earnings data on Monday, February 23rd. The technology company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. The company had revenue of $258.35 million during the quarter, compared to analysts’ expectations of $260.72 million. Novanta had a return on equity of 13.12% and a net margin of 5.49%.During the same quarter in the previous year, the company posted $0.76 earnings per share. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q1 2026 guidance at 0.750-0.800 EPS. On average, analysts forecast that Novanta Inc. will post 3.03 earnings per share for the current year.

Insider Transactions at Novanta

In other news, CFO Robert Buckley sold 1,423 shares of the business’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $140.88, for a total value of $200,472.24. Following the completion of the sale, the chief financial officer owned 93,814 shares of the company’s stock, valued at approximately $13,216,516.32. The trade was a 1.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Matthijs Glastra sold 7,500 shares of the stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $145.04, for a total transaction of $1,087,800.00. Following the transaction, the chief executive officer owned 57,367 shares in the company, valued at approximately $8,320,509.68. The trade was a 11.56% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 24,346 shares of company stock valued at $3,382,737. 1.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on NOVT shares. Robert W. Baird set a $150.00 price target on Novanta in a research report on Wednesday, February 25th. Weiss Ratings upgraded Novanta from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 20th. Finally, Zacks Research raised Novanta from a “strong sell” rating to a “hold” rating in a report on Friday, January 16th. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $150.00.

Novanta Company Profile

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.